Quest Diagnostics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
In 2024, we acquired the physician outreach business of OhioHealth, of University Hospitals, two big, large healthcare systems in Ohio. We acquired the physician outreach business of Allina Health towards the end of 2024 as well, or in 2024. Those have allowed us to gain share in the market, and we continue to see the benefit of that this year as well. We will do more of those acquisitions as they come up, again, strategically, where we have good access, but maybe not as much capture as we would like.
Those are generally accretive relatively quickly, I bet.
Absolutely, yeah. There are some integration costs at the front end. You have to get the systems to integrate between the health system and our systems. But within a short period of time, they get to our enterprise margins.
Tycho, maybe just thinking about the hospital channel and Co-Lab, I know it is a billion-dollar kind of plus business. You talked about getting to $2 billion, I think over the next couple years. Can you just talk to the funnel as it relates to new customers, and how do new customer wins contribute to growth versus just expansion with existing accounts?
Yeah, it's definitely an active funnel. I mean, we started this business back in around 2016 or so, really from nothing, and we built this business. Really, just for the audience here, the business is about running the inpatient lab of a health system, of a hospital, where we take over the lab and we provide savings and benefits in terms of guaranteed savings to the hospital. We get also some savings as well, or benefits, I should say, on running that lab. So we have a guaranteed margin. They have a certain amount of savings that they get. Corewell was a big Co-Lab partnership that we onboarded this year. It's about 20-plus hospitals that we run their inpatient lab. The funnel is very active in terms of these partnerships.
I think more and more, as hospitals require the support and the help of large independent labs like us, they turn to us for savings, for basically personnel savings or savings on their cost of employees, savings on their cost of procurement, on their contracts with different vendors, and we can help them gain synergies on that. The funnel is active. I think we've got a good set of potential partnerships that we have an eye towards.
Obviously, a lot of people focus on kind of some of the hospital pressures, ACA reform. I guess, are you seeing an acceleration in those conversations?
To some extent. I mean, the funnel has been pretty vibrant, I would say, or healthy, both in terms of Co-Lab partnerships and physician outreach acquisitions for some time. But listen, as these pressures, they're definitely not abating. I mean, these pressures are escalating for health systems, whether it's the healthcare exchange subsidies being eliminated, whether it's Medicaid work eligibility requirements driving more uninsured patients into their care, sometimes patients that can't pay. We are in a, I would say, a privileged position as Quest to have the scale, to have the means, the ability, the financial strength to be able to support the hospitals and support patients as well. So, that is something that's definitely that we're focused on. Yes, I mean, I think these conversations are increasing.
How do you think about the margin profile? I know Corewell and Fresenius have come in below corporate margins. You are doing some reinvestment there. At maturity, can Co-Lab approach corporate margins?
Co-Lab is Here is the thing about Co-Lab. The margins are always going to be, in terms of at least margin rate, are always going to be less than our enterprise margins. If our enterprise margins today are somewhere around 16%-17% operating margin rate, Co-Lab will be somewhere in the low double digits, maybe in the either low teens or 12%-13% margin rates. But the thing about Co-Lab is virtually very little capital deployment. The return on invested capital is really high on those businesses. So, I am less concerned about margin rate on Co-Lab, more concerned about shareholder return and ROIC and how we can generate return on invested capital. It is a very, very attractive profile in terms of return on invested capital on those businesses.
Now, to your question about Corewell, for instance, when we onboard those businesses, and with Corewell, we onboarded a very large Co-Lab relationship, $250 million approximately of revenues in 2026. Usually, you start out at lower margins until you can get the relationship set up, get past the integration costs, and then you start to see the margins improve, which is what we are seeing with Corewell right now.
I think, Co-Lab versus buying outreach, you talked last quarter, obviously, you acquired some outreach assets from a longtime Co-Lab customer. How do you think about the trade-offs there between running a hospital lab through Co-Lab versus just owning the outreach book of business?
Yeah, I like to think of it, Tycho, as an and, not an or. Both are really accretive for us as a business. As I said, there are a lot of ways that we can support our health system partners, and we can either support them by running their inpatient lab as a Co-Lab relationship, where, as I said earlier, we can guarantee them certain savings, get some return as a result as well, or we can purchase that physician outreach book of business from them, which is what we've done with the examples that I gave around OhioHealth, University Hospitals. The way that physician outreach works is you have a health system that has basically affiliated physicians that send their lab work to the hospital.
For the same reasons that a hospital decides to let us run their inpatient lab, they decide that labs is just not a strategic area for them. They have this opportunity to sell their physician outreach business to an independent, large independent lab like us. They monetize that. They get a capital injection to support some of their other strategic goals and their growth aspirations, and that lab work automatically transfers to us, where now the patients basically get sent to either our patient service centers and the testing gets done in a Quest lab. Or, in-office phlebotomist at a physician office draws the blood and the physician sends the work to Quest. It's a pretty easy lift and shift in terms of moving that volume to a Quest lab.
Okay. PAMA, you talked about a 1% potential revenue hit if it goes through. I guess, is there still a path in your view for RESULTS, after reform, and then what milestones should we be watching between now and year-end?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
1 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
